Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab

A restrospective analysis from the ObservEr study

Gerardo Rosati, Carmine Pinto, Francesca Di Fabio, Silvana Chiara, Ivan R Lolli, Enzo M Ruggeri, Libero Ciuffreda, Raimondo Ferrara, Lorenzo Antonuzzo, Daniela Adua, Patrizia Racca, Domenico Bilancia, Elena Benincasa, Maria Elena Stroppolo, Francesco Di Costanzo

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC).

METHODS: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires.

RESULTS: The two patient groups (141 < 70 and 84 ≥ 70 years, respectively) were balanced with no differences in any of the clinical and pathological characteristics considered. Both groups underwent similar type of first-line chemotherapy plus cetuximab, treatment duration and compliance. Cetuximab therapy caused similar incidence of side effects and impact on QoL in older and younger patients. No difference was observed in progression free survival (PFS) and in disease control rates between the two patient populations. Median overall survival (OS) was higher in patients <70 (27 months, 95% CI: 22.7-31.27) than in patients ≥70 (19 months, 95% CI: 14.65-23.35) (p = 0.002), which is likely due to higher proportions of metastatic resection (27.0% vs 8.3%; p = 0.001) and utilization of second-line therapy in younger group (58.9% vs 42.9%; p = 0.028).

CONCLUSION: The current data suggest that fit older patients with mCRC can be safely treated with a cetuximab-based therapy, as QoL and safety profile do not seem to be affected by age. In addition, age did not impact the choice of chemotherapy to be associated to cetuximab and treatment compliance.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalJournal of Geriatric Oncology
Volume9
Issue number3
DOIs
Publication statusPublished - May 2018

Fingerprint

Compliance
Quality of Life
Safety
Drug Therapy
Neoplasms
Colorectal Neoplasms
Therapeutics
Cetuximab
Incidence
Disease-Free Survival
Skin
Survival
Population

Cite this

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab : A restrospective analysis from the ObservEr study. / Rosati, Gerardo; Pinto, Carmine; Di Fabio, Francesca; Chiara, Silvana; Lolli, Ivan R; Ruggeri, Enzo M; Ciuffreda, Libero; Ferrara, Raimondo; Antonuzzo, Lorenzo; Adua, Daniela; Racca, Patrizia; Bilancia, Domenico; Benincasa, Elena; Stroppolo, Maria Elena; Di Costanzo, Francesco.

In: Journal of Geriatric Oncology, Vol. 9, No. 3, 05.2018, p. 243-248.

Research output: Contribution to journalArticle

Rosati, G, Pinto, C, Di Fabio, F, Chiara, S, Lolli, IR, Ruggeri, EM, Ciuffreda, L, Ferrara, R, Antonuzzo, L, Adua, D, Racca, P, Bilancia, D, Benincasa, E, Stroppolo, ME & Di Costanzo, F 2018, 'Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study', Journal of Geriatric Oncology, vol. 9, no. 3, pp. 243-248. https://doi.org/10.1016/j.jgo.2018.01.009
Rosati, Gerardo ; Pinto, Carmine ; Di Fabio, Francesca ; Chiara, Silvana ; Lolli, Ivan R ; Ruggeri, Enzo M ; Ciuffreda, Libero ; Ferrara, Raimondo ; Antonuzzo, Lorenzo ; Adua, Daniela ; Racca, Patrizia ; Bilancia, Domenico ; Benincasa, Elena ; Stroppolo, Maria Elena ; Di Costanzo, Francesco. / Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab : A restrospective analysis from the ObservEr study. In: Journal of Geriatric Oncology. 2018 ; Vol. 9, No. 3. pp. 243-248.
@article{0156391547ae481e8fac480e2b0e4e64,
title = "Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study",
abstract = "OBJECTIVES: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC).METHODS: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires.RESULTS: The two patient groups (141 < 70 and 84 ≥ 70 years, respectively) were balanced with no differences in any of the clinical and pathological characteristics considered. Both groups underwent similar type of first-line chemotherapy plus cetuximab, treatment duration and compliance. Cetuximab therapy caused similar incidence of side effects and impact on QoL in older and younger patients. No difference was observed in progression free survival (PFS) and in disease control rates between the two patient populations. Median overall survival (OS) was higher in patients <70 (27 months, 95{\%} CI: 22.7-31.27) than in patients ≥70 (19 months, 95{\%} CI: 14.65-23.35) (p = 0.002), which is likely due to higher proportions of metastatic resection (27.0{\%} vs 8.3{\%}; p = 0.001) and utilization of second-line therapy in younger group (58.9{\%} vs 42.9{\%}; p = 0.028).CONCLUSION: The current data suggest that fit older patients with mCRC can be safely treated with a cetuximab-based therapy, as QoL and safety profile do not seem to be affected by age. In addition, age did not impact the choice of chemotherapy to be associated to cetuximab and treatment compliance.",
author = "Gerardo Rosati and Carmine Pinto and {Di Fabio}, Francesca and Silvana Chiara and Lolli, {Ivan R} and Ruggeri, {Enzo M} and Libero Ciuffreda and Raimondo Ferrara and Lorenzo Antonuzzo and Daniela Adua and Patrizia Racca and Domenico Bilancia and Elena Benincasa and Stroppolo, {Maria Elena} and {Di Costanzo}, Francesco",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2018",
month = "5",
doi = "10.1016/j.jgo.2018.01.009",
language = "English",
volume = "9",
pages = "243--248",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab

T2 - A restrospective analysis from the ObservEr study

AU - Rosati, Gerardo

AU - Pinto, Carmine

AU - Di Fabio, Francesca

AU - Chiara, Silvana

AU - Lolli, Ivan R

AU - Ruggeri, Enzo M

AU - Ciuffreda, Libero

AU - Ferrara, Raimondo

AU - Antonuzzo, Lorenzo

AU - Adua, Daniela

AU - Racca, Patrizia

AU - Bilancia, Domenico

AU - Benincasa, Elena

AU - Stroppolo, Maria Elena

AU - Di Costanzo, Francesco

N1 - Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - OBJECTIVES: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC).METHODS: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires.RESULTS: The two patient groups (141 < 70 and 84 ≥ 70 years, respectively) were balanced with no differences in any of the clinical and pathological characteristics considered. Both groups underwent similar type of first-line chemotherapy plus cetuximab, treatment duration and compliance. Cetuximab therapy caused similar incidence of side effects and impact on QoL in older and younger patients. No difference was observed in progression free survival (PFS) and in disease control rates between the two patient populations. Median overall survival (OS) was higher in patients <70 (27 months, 95% CI: 22.7-31.27) than in patients ≥70 (19 months, 95% CI: 14.65-23.35) (p = 0.002), which is likely due to higher proportions of metastatic resection (27.0% vs 8.3%; p = 0.001) and utilization of second-line therapy in younger group (58.9% vs 42.9%; p = 0.028).CONCLUSION: The current data suggest that fit older patients with mCRC can be safely treated with a cetuximab-based therapy, as QoL and safety profile do not seem to be affected by age. In addition, age did not impact the choice of chemotherapy to be associated to cetuximab and treatment compliance.

AB - OBJECTIVES: The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions) and efficacy of chemotherapy plus cetuximab in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC).METHODS: 225 patients of the Observed study (PS 0-1) were retrieved based on age (< 70 and ≥70 years) and evaluated through EORTC QLQ-C30 and DLQI questionnaires.RESULTS: The two patient groups (141 < 70 and 84 ≥ 70 years, respectively) were balanced with no differences in any of the clinical and pathological characteristics considered. Both groups underwent similar type of first-line chemotherapy plus cetuximab, treatment duration and compliance. Cetuximab therapy caused similar incidence of side effects and impact on QoL in older and younger patients. No difference was observed in progression free survival (PFS) and in disease control rates between the two patient populations. Median overall survival (OS) was higher in patients <70 (27 months, 95% CI: 22.7-31.27) than in patients ≥70 (19 months, 95% CI: 14.65-23.35) (p = 0.002), which is likely due to higher proportions of metastatic resection (27.0% vs 8.3%; p = 0.001) and utilization of second-line therapy in younger group (58.9% vs 42.9%; p = 0.028).CONCLUSION: The current data suggest that fit older patients with mCRC can be safely treated with a cetuximab-based therapy, as QoL and safety profile do not seem to be affected by age. In addition, age did not impact the choice of chemotherapy to be associated to cetuximab and treatment compliance.

U2 - 10.1016/j.jgo.2018.01.009

DO - 10.1016/j.jgo.2018.01.009

M3 - Article

VL - 9

SP - 243

EP - 248

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

IS - 3

ER -